Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Medicenna Therapeutics Corp. announced promising clinical trial results for its immunotherapy drug MDNA11, showing significant tumor regression in melanoma and pancreatic cancer patients who were previously resistant to other treatments. The company has also secured a financial investment extending its operational runway to mid-2026 and plans to present further updates in the second half of 2024.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
